前列腺动脉栓塞新辅助治疗后放疗的泌尿症状改善持久性
单中心回顾性研究纳入82例PAE后接受根治性前列腺放疗的患者,评估新辅助PAE带来的下尿路症状(LUTS)改善在放疗后的持久性及肿瘤学结局。PAE后IPSS平均降低10.7分,前列腺体积平均缩小32%;放疗后24个月内IPSS改善持续存在(各时间点p<0.001),中位随访24.2个月仅1例局部复发,非转移患者2年bRFS为92%。
要点
- PAE后IPSS平均降低10.7分,前列腺体积平均缩小32%。
- 放疗后3–24个月IPSS改善持续存在,各时间点p<0.001。
- 中位随访24.2个月仅1例局部复发,非转移患者2年bRFS为92%。
核心结论
- 对于前列腺体积大和/或LUTS负担高的男性,新辅助PAE后放疗的泌尿症状改善是持久的,且中期随访未增加复发风险。
研究设计与样本
- 单中心回顾性研究,从前瞻性数据库筛选2017年9月至2024年5月接受PAE后根治性前列腺放疗的患者共82例,30.5%为不利中危。
- 放疗方式包括常规分割(n=21)、中度大分割(n=42)、SBRT(n=11)和EBRT/近距离放疗推量(n=8),部分患者接受雄激素剥夺治疗,28例(34%)接受盆腔淋巴结治疗。
- 主要终点为IPSS评估的LUTS,次要终点包括生化无复发生存(bRFS)、局部复发和远处转移,毒性按CTCAEv5.0评估。
主要发现
- PAE前中位IPSS为18(范围2–34),前列腺体积90 cc(14.2–240),PSA 8.4 ng/mL(0.02–125.5)。
- PAE后IPSS平均降低10.7分(范围-13–30),前列腺体积平均缩小30.9 cc(范围-9–136)或32%。
- PAE使52%因体积/IPSS禁忌近距离放疗/SBRT的患者转为可接受。
- 放疗后3、6、12、18、24个月IPSS平均变化分别为-8.7、-8.5、-9.5、-8.9、-7.6(p<0.001)。
- 中位随访24.2个月,1例局部复发,非转移患者2年bRFS为92%。
关键数值与推荐
- PAE后IPSS平均降低10.7分,前列腺体积平均缩小30.9 cc或32%。
- 放疗后3–24个月IPSS平均变化为-8.7至-7.6分,各时间点p<0.001。
- 非转移患者2年bRFS为92%,中位随访24.2个月仅1例局部复发。
临床怎么用
- 对前列腺体积大和/或LUTS负担高、拟行放疗的患者,可考虑新辅助PAE以改善泌尿症状并增加近距离放疗/SBRT可行性。
- PAE后放疗的泌尿症状改善可维持至放疗后24个月,中期肿瘤学结局未见明显不利信号。
局限性
- 单中心回顾性研究,样本量82例,随访中期(中位24.2个月),需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation therapy (RT) for prostate cancer has gastrointestinal and genitourinary toxicities, greater with baseline lower urinary tract symptoms (LUTS) and larger prostate volume (PV). Prostate artery embolization (PAE) improves LUTS and PV before RT. This study evaluates the durability of LUTS improvement from neoadjuvant PAE before prostate RT and oncologic outcomes. METHODS: We retrospectively identified patients receiving definitive prostate RT following PAE from a prospective database, including International Prostate Symptom Scores (IPSS), pre- and post-PAE MRI PV, and toxicity per CTCAEv5.0. Primary objective was LUTS by IPSS. Secondary objectives included biochemical recurrence-free survival (bRFS), local recurrence, and distant metastasis. RESULTS: From 9/2017-5/2024, 82 patients underwent PAE before RT, with 30.5 % having unfavorable intermediate risk. RT consisted of conventional fractionation (n = 21), moderate hypofractionation (n = 42), SBRT (n = 11), and EBRT/brachytherapy boost (n = 8); a subset of patients received androgen deprivation therapy. Pelvic lymph nodes were treated in 28 (34 %) patients. Median pre-PAE IPSS was 18 (range 2-34), PV 90 cc (14.2-240), and PSA 8.4 ng/mL (0.02-125.5). Post-PAE, mean IPSS reduction was 10.7 points (-13-30). Mean PV reduction was 30.9 cc (-9-136) or 32 %. PAE converted 52 % of patients contraindicated by size/IPSS for brachytherapy/SBRT. Post-RT, mean IPSS changes at 3, 6, 12, 18 and 24 months were -8.7, -8.5, -9.5, -8.9, and -7.6, respectively (p < 0.001). At 24.2-month median follow-up, 1 local recurrence occurred. Two-year bRFS was 92 % for non-metastatic patients. CONCLUSION: Urinary improvement is durable after RT in men with large prostates and/or high LUTS burden with neoadjuvant PAE, and no increased risk of recurrence at intermediate-term follow-up. Further investigation is warranted.
引用
- Khatri VM, Grass GD, Thapa R, et al. Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation. Clin Transl Radiat Oncol. 2025. PMID: 41122670. doi:10.1016/j.ctro.2025.101035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。